(ALBT) Avalon GloboCare - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
ALBT: Real Estate, Laboratory Services, Diagnostic Assets, Genetic Testing
Avalon GloboCare Corp. (NASDAQ:ALBT) operates as a commercial real estate owner and developer in the United States, focusing on property acquisition and management. The company also engages in the development of precision diagnostics and clinical laboratory services through strategic acquisitions, joint ventures, and distribution rights. Established in 2016, it is headquartered in Freehold, New Jersey. Web URL: https://www.avalon-globocare.com
Based on
Additional Sources for ALBT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ALBT Stock Overview
Market Cap in USD | 12m |
Sector | Real Estate |
Industry | Real Estate Services |
GiC Sub-Industry | Real Estate Development |
IPO / Inception | 2016-12-06 |
ALBT Stock Ratings
Growth 5y | -87.8% |
Fundamental | -7.36% |
Dividend | 0.0% |
Rel. Strength Industry | -22.1 |
Analysts | - |
Fair Price Momentum | 2.68 USD |
Fair Price DCF | - |
ALBT Dividends
No Dividends PaidALBT Growth Ratios
Growth Correlation 3m | 53.6% |
Growth Correlation 12m | -39.6% |
Growth Correlation 5y | -98.2% |
CAGR 5y | -49.91% |
CAGR/Max DD 5y | -0.50 |
Sharpe Ratio 12m | -0.68 |
Alpha | -19.91 |
Beta | 0.20 |
Volatility | 263.83% |
Current Volume | 69k |
Average Volume 20d | 111.7k |
As of March 16, 2025, the stock is trading at USD 4.89 with a total of 68,958 shares traded.
Over the past week, the price has changed by -32.37%, over one month by +32.52%, over three months by +26.68% and over the past year by -14.44%.
Neither. Based on ValueRay Fundamental Analyses, Avalon GloboCare is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALBT as of March 2025 is 2.68. This means that ALBT is currently overvalued and has a potential downside of -45.19%.
Avalon GloboCare has no consensus analysts rating.
According to ValueRays Forecast Model, ALBT Avalon GloboCare will be worth about 2.9 in March 2026. The stock is currently trading at 4.89. This means that the stock has a potential downside of -40.7%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 2.9 | -40.7% |